WA
UTHR icon

Waystone Advisors’s United Therapeutics UTHR Stock Holding History

Waystone Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$295K Buy
544
+3
+0.6% +$1.69K 0.22% 93
2026
Q1 		$321K Sell
541
-87
-14% -$43.3K 0.29% 83
2025
Q4 		$306K Buy
+628
New +$292K 0.26% 86

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Waystone Advisors's UTHR Position: Q2 2026 in Review

Waystone Advisors increased its United Therapeutics (UTHR) stake by 0.55% in Q2 2026, buying an estimated $1.69K and bringing the position to 544 shares worth $295K. The position accounts for 0.22% of the portfolio, ranked #93.

Waystone Advisors first reported a position in UTHR in Q4 2025 and has held it in 3 quarters since. The position peaked at $321K in Q1 2026. 878 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Waystone Advisors held 544 shares of United Therapeutics worth $295K as of Q2 2026.
  • Waystone Advisors bought 3 United Therapeutics shares in Q2 2026, an estimated $1.69K.
  • United Therapeutics made up 0.22% of Waystone Advisors's portfolio in Q2 2026, its #93 holding.
  • Waystone Advisors first reported a position in United Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Waystone Advisors's United Therapeutics position peaked at $321K in Q1 2026.
  • 878 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Waystone Advisors's 13F filing for Q2 2026, filed 16 Jul 2026.